Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814182 | 0.83 | RECQL (0.42) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL4814188 | 0.83 | RECQL (0.42) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL1709282 | 0.82 | MEN1 (0.48) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL19876221 | 0.81 | CA12 (0.41) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL23299718 | 0.81 | RECQL (0.41) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL8558174 | 0.81 | RECQL (0.50) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL4742448 | 0.81 | RECQL (0.41) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL7376338 | 0.81 | RECQL (0.41) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL20829083 | 0.81 | RECQL (0.41) | MEN1KMT2ARECQLGAACA12 | |
| SCHEMBL2842538 | 0.81 | RECQL (0.41) | MEN1KMT2ARECQLGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4227300-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-11084796-B2 | Heterocyclic derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | RAJASEKHAR VIJAYKUMAR (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190135770-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015757-A1 | Novel Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MEN1 887/4885KMT2A 242/4885RECQL 4021/4885 |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | FH, FAH, ALDOA | MEN1 1212/4885KMT2A 578/4885RECQL 1513/4885 |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | FH, HMGCR, HPGD | MEN1 2286/4885KMT2A 1017/4885RECQL 2142/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | MEN1 855/4885KMT2A 1619/4885RECQL 1743/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | MEN1 1620/4885KMT2A 438/4885RECQL 3124/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MEN1 887/4885KMT2A 242/4885RECQL 4021/4885 |
| US-20190135770-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | MAVS, HMGB3, NIPSNAP3A | MEN1 3791/4885KMT2A 3637/4885RECQL 440/4885 |
| US-20070015757-A1 | Novel Glucagon Antagonists/Inverse Agonists | GLP1R, GCGR, GIPR | MEN1 1961/4885KMT2A 3612/4885RECQL 4779/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | MEN1 3481/4885KMT2A 4343/4885RECQL 1414/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | MEN1 1212/4885KMT2A 578/4885RECQL 1513/4885 |
| US-11084796-B2 | Heterocyclic derivatives for the treatment of RSV | MAVS, HMGB3, NIPSNAP3A | MEN1 3791/4885KMT2A 3637/4885RECQL 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.